ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zai Lab's revenue per share for the three months ended in Sep. 2024 was $1.04. Zai Lab's revenue per share for the trailing twelve months (TTM) ended in Sep. 2024 was $3.65.
Warning Sign:
Zai Lab Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Zai Lab was 33.40% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 63.60% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 254.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Zai Lab's Revenue per Share or its related term are showing as below:
During the past 9 years, Zai Lab's highest 3-Year average Revenue Per Share Growth Rate was 818.90% per year. The lowest was 63.60% per year. And the median was 123.20% per year.
The historical data trend for Zai Lab's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Revenue per Share | Get a 7-Day Free Trial | 0.20 | 0.63 | 1.55 | 2.25 | 2.76 |
Zai Lab Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Revenue per Share | Get a 7-Day Free Trial | 0.72 | 0.68 | 0.90 | 1.03 | 1.04 |
For the Biotechnology subindustry, Zai Lab's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zai Lab's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zai Lab's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Zai Lab's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue Per Share (A: Dec. 2023 ) | = | Revenue (A: Dec. 2023 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2023 ) |
= | 266.719 | / | 96.639 | |
= | 2.76 |
Zai Lab's Revenue Per Share for the quarter that ended in Sep. 2024 is calculated as
Revenue Per Share (Q: Sep. 2024 ) | = | Revenue (Q: Sep. 2024 ) | / | Shares Outstanding (Diluted Average) (Q: Sep. 2024 ) |
= | 102.265 | / | 98.169 | |
= | 1.04 |
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (NAS:ZLAB) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Zai Lab's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Yajing Chen | officer: Chief Financial Officer | 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Edmondson Frazor Titus Iii | officer: Chief Legal Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Joshua L Smiley | officer: Chief Operating Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Rafael Amado | officer: See Remarks | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Ying Du | director, officer: Chairwoman & CEO | C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210 |
Harald Reinhart | officer: Chief Medical Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Michel Vounatsos | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Peter Wirth | director | 37 HANCOCK STREET, BOSTON MA 02114 |
John D Diekman | director | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Tao Fu | director, officer: President & COO | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Cho William Ki Chul | officer: Chief Financial Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Kai-xian Chen | director | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
From GuruFocus
By Business Wire • 08-22-2024
By Business Wire • 08-27-2024
By Business Wire • 10-24-2024
By GuruFocus News • 11-08-2024
By GuruFocus Research • 08-08-2024
By Business Wire • 11-21-2024
By Business Wire • 10-16-2024
By Business Wire • 12-02-2024
By GuruFocus Research • 08-08-2024
By GuruFocus News • 10-24-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.